Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs
Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round
Funds to be used to continue developing proprietary platform to rapidly identify synthetically lethal interactions to improve cancer care
Raleigh investor bets big on Duke oncology spin-out Tavros
A Duke University spin-out focused on cancer treatment is getting financial backing from a Raleigh-based investment fund.
Durham biotech startup founded by Duke grad raises nearly $1M in equity
DURHAM – Tavros Therapeutics, an emerging biotechnology company based out of Durham, has raised nearly $1 million in equity, according to a recent securities filing, and is working to discover “a new frontier” in oncology therapy.
Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies
NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply Tavros’ functional genomic discovery platform to develop next generation targeted small molecule drug candidates, initially to expand Zentalis’ oncology pipeline.